Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ASCENDIS PHARMA A/S

(ASND)
  Report
Delayed Nasdaq  -  04:00 2022-12-01 pm EST
121.75 USD   -1.06%
11/30European Equities Nudge Higher on Slightly Lower Euro Area Inflation
MT
11/22Ascendis Pharma to Participate in the 5th Annual Evercore ISI HealthCONx Conference
AQ
11/16European Equities Flat in Choppy Trade Wednesday as Geopolitical Tensions Weigh
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Transcript : Ascendis Pharma A/S Presents at Morgan Stanley 20th Annual Global Healthcare Conference, Sep-13-2022 01:30 PM

09/13/2022 | 01:30pm EST
Welcome. Let's go ahead and get started. This is the fireside chat with Ascendis Pharma. My name is Vikram Purohit and I'm one of the Biotech Analyst with Morgan Stanley Research. I need to read a...


ę S&P Capital IQ 2022
All news about ASCENDIS PHARMA A/S
11/30European Equities Nudge Higher on Slightly Lower Euro Area Inflation
MT
11/22Ascendis Pharma to Participate in the 5th Annual Evercore ISI HealthCONx Conference
AQ
11/16European Equities Flat in Choppy Trade Wednesday as Geopolitical Tensions Weigh
MT
11/15Morgan Stanley Adjusts Price Target on Ascendis Pharma to $148 From $146, Maintains Ove..
MT
11/15Ascendis Pharma Submits Marketing Authorisation Application to the European Medicines A..
AQ
11/14European ADRs Continue to Trend Higher in Monday Trading
MT
11/14Ascendis Pharma Submits Marketing Authorization Application in EU for Hypoparathyroidis..
MT
11/14Dose Escalation Data from transcendIT-101 Ascendis Pharma's Phase 1/2 Trial of TransCon..
AQ
11/14Once-Weekly TransCon CNP Achieved Primary Efficacy Objective, with Superiority at 100 -..
AQ
11/14Transcript : Ascendis Pharma A/S - Special Call
CI
More news
Analyst Recommendations on ASCENDIS PHARMA A/S
More recommendations
Financials
Sales 2022 47,4 M 48,9 M 48,9 M
Net income 2022 -528 M -544 M -544 M
Net cash 2022 513 M 530 M 530 M
P/E ratio 2022 -12,5x
Yield 2022 -
Capitalization 6 668 M 6 876 M 6 876 M
EV / Sales 2022 130x
EV / Sales 2023 44,0x
Nbr of Employees 639
Free-Float 10,3%
Chart ASCENDIS PHARMA A/S
Duration : Period :
Ascendis Pharma A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASCENDIS PHARMA A/S
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 15
Last Close Price 119,33 €
Average target price 154,17 €
Spread / Average Target 29,2%
EPS Revisions
Managers and Directors
Jan M°ller Mikkelsen President, CEO & Executive Director
Scott Thomas Smith Chief Financial Officer & Senior Vice President
Albert Cha Chairman
Birgitte Volck SVP, Head-Clinical Development & Medical Affairs
Kennett Sprog°e Senior Vice President, Head-Innovation & Research
Sector and Competitors
1st jan.Capi. (M$)
ASCENDIS PHARMA A/S-9.50%6 876
VERTEX PHARMACEUTICALS46.07%81 217
REGENERON PHARMACEUTICALS, INC.19.03%80 283
BIONTECH SE-34.26%40 589
WUXI APPTEC CO., LTD.-34.22%32 137
GENMAB A/S25.29%29 594